Skip to content
Xbiome logo — China's leading AI-driven microbiome drug development compan...

Xbiome

China's leading AI-driven microbiome drug development company

Founded 2017 United States Cambridge, United States 48 employees Series B Total: $210.00M AI, Biotechnology +1

General Information

Company Name Xbiome
Founded Year 2017
Location United States Cambridge, United States
Employees 48
Industries AI, Biotechnology, Pharmaceutical
Funding Stage Series B
Business Model B2B, Platform, SaaS
Revenue Model Licensing, Performance Based, Subscription
Social

BounceWatch is an independent company data service, not affiliated with Xbiome. To contact Xbiome, visit xbiome.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Xbiome compare?

A PDF of Xbiome and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Xbiome soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Xbiome

Xbiome, established in 2017, is touted as China's leading AI-driven microbiome drug development company. As a pioneer in AI-based solutions, it aims to transform the biotechnology and pharmaceutical sectors, focusing on gut microbiome using sophisticated AI techniques. This approach to health leverages the gut's microbial ecosystem, known to affect over 50 human diseases, by harnessing AI and bioinformatics for drug development.

Their innovative platform, which integrates microbial technologies and gut microbiome insights, significantly enhances the speed and success rate of new treatments. With headquarters in the United States, Xbiome is poised for significant growth, reflected in their robust Series B investment of $100.00M as of December 22, 2021. The funding round saw contributions from prominent investors like Gaorong Capital, Sky9 Capital, and Legend Capital among others. This solid backing and innovative approach position Xbiome as a compelling opportunity for investors focused on the future of personalized medicine.

Business keywords: AI-driven drug development, Microbiome therapeutics, Gut health management, Personalized medicine, Bioinformatics, Microbial technology, Intestinal micro-ecology, Pharmaceutical innovation, Dysbiosis solutions, Microbiota analysis, Artificial intelligence in healthcare, Precision health, Microbial ecosystem analysis, Human microbiome

Services & Products

Technology Platform Development
Pharmaceutical Research
Drug Pipeline Management
Collaboration with Scientific and Medical Communities

Target Customers

Biotech and Pharma Companies Healthcare Organizations Research Institutions Scientific Community

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Series B $100.00M 8
Gaorong Capital, Sky9 Capital +6
22 Dec 2021
Series B Undisclosed 2
Gaorong Capital, Legend Capital
27 Nov 2020
Series B CNY100.00M -
02 Nov 2019
Series A $10.00M -
24 Jun 2019

Xbiome Alternatives & Competitors

View All Alternatives
Xbiome vs

We build generative AI for protein therapeutics.

9 employees
Biotechnology, Pharmaceutical
Xbiome vs
iLOF
iLOF United Kingdom

Using AI and Photonics to enable a new era of personalized, precision medicine.

Venture round
42 employees
AI, Biotechnology
Xbiome vs
Parallel Bio
Parallel Bio United States

Using the immune system to cure disease.

Series A
27 employees
Biotechnology, Health and Wellness

FAQ About Xbiome

China's leading AI-driven microbiome drug development company
Xbiome was founded in 2017.
Xbiome is headquartered in Cambridge, United States.
Xbiome operates in AI, Biotechnology and Pharmaceutical. Its work centres on AI-driven drug development, Microbiome therapeutics, Gut health management and Personalized medicine. Its customers include Biotech and Pharma Companies, Healthcare Organizations and Research Institutions.
Xbiome has a B2B, Platform and SaaS business model. Its revenue comes from Licensing, Performance Based and Subscription.
Xbiome has approximately 48 employees.
Xbiome has completed 4 funding rounds, raising a total of $210.00M. The latest funding stage is Series B.
Xbiome offers: Technology Platform Development, Pharmaceutical Research, Drug Pipeline Management, Collaboration with Scientific and Medical Communities.
Top alternatives and competitors to Xbiome include Diffuse Bio, iLOF, Parallel Bio, Tempus AI, mybacs. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Xbiome and Diffuse Bio are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Xbiome, https://bouncewatch.com/company/xbiome, updated 6 November 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout